Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis

Summary

A study of UCB4940 in subjects with psoriatic arthritis to evaluate the safety and body distribution of UCB4940 in those patients. Neither the patient nor the doctor will know the treatment group.

Conditions

• Psoriatic Arthritis

Interventions

DRUG

UCB4940 40 mg

* Active Substance: UCB4940 * Pharmaceutical Form: solution * Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose * Route of Administration: intravenous

DRUG

UCB4940 80 mg

* Active Substance: UCB4940 * Pharmaceutical Form: solution * Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose * Route of Administration: intravenous

DRUG

UCB4940 160 mg

* Active Substance: UCB4940 * Pharmaceutical Form: solution * Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose * Route of Administration: intravenous

DRUG

UCB4940 240 mg

* Active Substance: UCB4940 * Pharmaceutical Form: solution * Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose * Route of Administration: intravenous

DRUG

UCB4940 320 mg

* Active Substance: UCB4940 * Pharmaceutical Form: solution * Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose * Route of Administration: intravenous

DRUG

UCB4940 560 mg

* Active Substance: UCB4940 * Pharmaceutical Form: solution * Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose * Route of Administration: intravenous

OTHER

Placebo

* Pharmaceutical Form: solution * Concentration: 0.9 % sodium chloride * Route of Administration: intravenous

Sponsors & Collaborators

• Parexel

  collaborator INDUSTRY

• MAC Clinical Research

  collaborator OTHER

• Comac Medical

  collaborator INDUSTRY

• ARENSIA, Moldova

  collaborator UNKNOWN

• UCB Celltech

  lead INDUSTRY

Principal Investigators

• UCB Clinical Trial Call Center · UCB Pharma

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-05-31

Primary Completion

2015-08-31

Completion

2015-08-31

Countries

• Bulgaria
• Moldova
• United Kingdom

Study Locations